Erlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation
Tyrosine kinase inhibitors of the first, second and third generations are the main treatment method for non-small cell lung cancer with EGFR mutation. About 60% of patients progressing on a first-generation or second-generation tyrosine kinase inhibitor acquire T790M mutation. An alternative is firs...
Na minha lista:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Russo |
| Udgivet: |
Remedium Group LLC
2021-08-01
|
| Serier: | Медицинский совет |
| Fag: | |
| Online adgang: | https://www.med-sovet.pro/jour/article/view/6247 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|